Celyad SA (CYAD): Price and Financial Metrics
Celyad SA (CYAD)
Today's Latest Price: $9.95 USD
Updated Nov 27 12:15pm
Add CYAD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
CYAD Stock Summary
- With a price/sales ratio of 20,807.91, Celyad Oncology SA has a higher such ratio than 99.89% of stocks in our set.
- With a year-over-year growth in debt of 529.59%, Celyad Oncology SA's debt growth rate surpasses 96.55% of about US stocks.
- As for revenue growth, note that CYAD's revenue has grown 94.83% over the past 12 months; that beats the revenue growth of 94.36% of US companies in our set.
- Stocks that are quantitatively similar to CYAD, based on their financial statements, market capitalization, and price volatility, are VNRX, TGTX, EIDX, AUPH, and PSTI.
- CYAD's SEC filings can be seen here. And to visit Celyad Oncology SA's official web site, go to www.celyad.com.
CYAD Stock Price Chart Interactive Chart >
CYAD Price/Volume Stats
| Current price | $9.95 | 52-week high | $13.01 |
| Prev. close | $9.63 | 52-week low | $4.10 |
| Day low | $9.73 | Volume | 11,200 |
| Day high | $9.95 | Avg. volume | 15,120 |
| 50-day MA | $8.87 | Dividend yield | N/A |
| 200-day MA | $9.39 | Market Cap | 138.72M |
Celyad SA (CYAD) Company Bio
Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Loading social stream, please wait...